Panbela Therapeutics (PBLA) Competitors $0.25 +0.00 (+1.66%) As of 06/11/2025 10:12 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. ONCO, DRMA, MTNB, INM, PLRZ, TCRT, KZIA, RDHL, TTNP, and THARShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Onconetix (ONCO), Dermata Therapeutics (DRMA), Matinas Biopharma (MTNB), InMed Pharmaceuticals (INM), Polyrizon (PLRZ), Alaunos Therapeutics (TCRT), Kazia Therapeutics (KZIA), RedHill Biopharma (RDHL), Titan Pharmaceuticals (TTNP), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Onconetix Dermata Therapeutics Matinas Biopharma InMed Pharmaceuticals Polyrizon Alaunos Therapeutics Kazia Therapeutics RedHill Biopharma Titan Pharmaceuticals Tharimmune Panbela Therapeutics (NASDAQ:PBLA) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation. Do institutionals and insiders believe in PBLA or ONCO? 4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by insiders. Comparatively, 3.1% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, PBLA or ONCO? Panbela Therapeutics has higher earnings, but lower revenue than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00Onconetix$2.52M1.75-$37.41MN/AN/A Do analysts rate PBLA or ONCO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, PBLA or ONCO? Panbela Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.5, meaning that its share price is 250% more volatile than the S&P 500. Does the media refer more to PBLA or ONCO? In the previous week, Onconetix had 3 more articles in the media than Panbela Therapeutics. MarketBeat recorded 4 mentions for Onconetix and 1 mentions for Panbela Therapeutics. Onconetix's average media sentiment score of 0.22 beat Panbela Therapeutics' score of -1.00 indicating that Onconetix is being referred to more favorably in the news media. Company Overall Sentiment Panbela Therapeutics Negative Onconetix Neutral Does the MarketBeat Community prefer PBLA or ONCO? Panbela Therapeutics received 18 more outperform votes than Onconetix when rated by MarketBeat users. CompanyUnderperformOutperformPanbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% OnconetixN/AN/A Is PBLA or ONCO more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -2,758.89%. Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Onconetix -2,758.89%N/A -48.09% SummaryOnconetix beats Panbela Therapeutics on 7 of the 11 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio0.008.8527.2320.02Price / SalesN/A256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book-0.016.617.124.70Net Income-$25.26M$143.93M$3.23B$247.97M7 Day Performance-11.65%3.84%2.74%2.64%1 Month Performance-14.92%11.14%8.94%6.39%1 Year Performance-37.25%4.35%31.59%13.95% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.0869 of 5 stars$0.25+1.7%N/A-41.6%$1.22MN/A0.006Negative NewsShort Interest ↑Gap DownONCOOnconetix0.7222 of 5 stars$0.07-10.3%N/A-98.9%$4.63M$1.87M0.0012News CoverageStock SplitShort Interest ↓DRMADermata Therapeutics3.0663 of 5 stars$0.72+2.1%$3.00+319.6%-75.3%$4.56MN/A-0.048Short Interest ↓MTNBMatinas Biopharma0.9011 of 5 stars$0.86+5.3%N/AN/A$4.39M$1.10M-0.1830Short Interest ↓High Trading VolumeINMInMed Pharmaceuticals0.8314 of 5 stars$3.63+6.1%N/A-46.7%$4.38M$4.92M-0.2610Short Interest ↓Gap DownPLRZPolyrizonN/A$0.82+6.0%N/AN/A$4.34MN/A0.00N/ANews CoveragePositive NewsGap UpTCRTAlaunos Therapeutics1.1448 of 5 stars$2.64-2.2%N/A-71.5%$4.33M$11K0.0040Gap UpKZIAKazia Therapeutics3.6161 of 5 stars$4.26+12.7%$57.50+1,249.8%-27.2%$4.29M$2.31M0.0012News CoverageAnalyst ForecastShort Interest ↓Gap DownRDHLRedHill Biopharma1.3073 of 5 stars$1.86+3.3%N/A-99.2%$4.26M$8.04M0.00210Upcoming EarningsTTNPTitan Pharmaceuticals1.2008 of 5 stars$4.58-6.1%N/A-30.1%$4.19M$180K-1.0010Positive NewsShort Interest ↓High Trading VolumeTHARTharimmune3.4152 of 5 stars$1.56+5.2%$17.00+991.6%-54.2%$4.14MN/A-0.202Gap Up Related Companies and Tools Related Companies Onconetix Competitors Dermata Therapeutics Competitors Matinas Biopharma Competitors InMed Pharmaceuticals Competitors Polyrizon Competitors Alaunos Therapeutics Competitors Kazia Therapeutics Competitors RedHill Biopharma Competitors Titan Pharmaceuticals Competitors Tharimmune Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBLA Stock Free PBLA Stock Alerts